3D Predict
Brain Mets Lung (NSCLC)
Key Facts
About Kiyatec
Kiyatec is a private, commercial-stage company pioneering a functional precision oncology platform. Its validated, CLIA-certified laboratory service uses live patient tumor tissue to create 3D microtumors, testing them against various drugs to predict clinical response within 7-10 days. With a focus on solid tumors, the company is generating early revenue from its diagnostic service while expanding its clinical pipeline. Kiyatec's approach addresses a critical unmet need in oncology by aiming to replace empirical treatment selection with data-driven predictions.
View full company profileAbout Kiyatec
Kiyatec is a private, commercial-stage company pioneering a functional precision oncology platform. Its validated, CLIA-certified laboratory service uses live patient tumor tissue to create 3D microtumors, testing them against various drugs to predict clinical response within 7-10 days. With a focus on solid tumors, the company is generating early revenue from its diagnostic service while expanding its clinical pipeline. Kiyatec's approach addresses a critical unmet need in oncology by aiming to replace empirical treatment selection with data-driven predictions.
View full company profileAbout Kiyatec
Kiyatec is a private, commercial-stage company pioneering a functional precision oncology platform. Its validated, CLIA-certified laboratory service uses live patient tumor tissue to create 3D microtumors, testing them against various drugs to predict clinical response within 7-10 days. With a focus on solid tumors, the company is generating early revenue from its diagnostic service while expanding its clinical pipeline. Kiyatec's approach addresses a critical unmet need in oncology by aiming to replace empirical treatment selection with data-driven predictions.
View full company profileAbout Kiyatec
Kiyatec is a private, commercial-stage company pioneering a functional precision oncology platform. Its validated, CLIA-certified laboratory service uses live patient tumor tissue to create 3D microtumors, testing them against various drugs to predict clinical response within 7-10 days. With a focus on solid tumors, the company is generating early revenue from its diagnostic service while expanding its clinical pipeline. Kiyatec's approach addresses a critical unmet need in oncology by aiming to replace empirical treatment selection with data-driven predictions.
View full company profileAbout Kiyatec
Kiyatec is a private, commercial-stage company pioneering a functional precision oncology platform. Its validated, CLIA-certified laboratory service uses live patient tumor tissue to create 3D microtumors, testing them against various drugs to predict clinical response within 7-10 days. With a focus on solid tumors, the company is generating early revenue from its diagnostic service while expanding its clinical pipeline. Kiyatec's approach addresses a critical unmet need in oncology by aiming to replace empirical treatment selection with data-driven predictions.
View full company profile